Aptorum Group Appoints Dr. Herman Weiss as CEO of microbiome-based platform Claves Life Sciences & Dr. Robbie Majzner as scie...
August 20 2020 - 2:00AM
Business Wire
Regulatory News:
Aptorum Group Limited (NASDAQ: APM, Euronext Paris: APM), a
biopharmaceutical company focused on the development of novel
therapeutics to address certain global unmet medical needs, today
announced two appointments to its team.
Appointment of Dr. Herman Weiss MD as
CEO and Executive Director of Claves Life Sciences
Dr. Herman Weiss, M.D., has been appointed as the Chief
Executive Officer and Executive Director of Claves Life Sciences
Limited (“Claves”) and also senior medical advisor of Aptorum Group
Limited (“Aptorum Group” or “Company”). Claves is one of Aptorum
Group’s wholly-owned subsidiaries and is focused on
microbiome-based approach to metabolic diseases. Going forward, Dr.
Weiss will be leading the development of Claves’ business and drive
Claves’ exciting microbiome-based research platform for treatments
of metabolic diseases, and potentially other indications, to
targeted clinical stages. Claves is a microbiome-based platform
utilizing proprietary macromolecule-based technology to target
major systemic metabolic diseases including microbiome modulator
CLS-1 for treatment of obesity. Through Claves, the Company is also
developing microbiome modulators CLS-2 and CLS-3, which target
other metabolic diseases.
Appointment of Dr. Robbie Majzner as
scientific advisor of Aptorum Group
Dr. Robbie Majzner has been appointed as a scientific advisor of
Aptorum Group Limited. In particular, Dr. Majzner will provide
scientific advice and support for certain targeted clinical
development aspects of Aptorum Group’s repurposed drug candidate
SACT-1 for the treatment of neuroblastoma, a rare type of solid
tumor cancer that develops predominantly in infants and young
children, as well as other potential cancer indications.
“We are delighted that Dr. Weiss and Dr. Majzner are joining the
Aptorum Group family. as the Chief Executive Officer of Claves, Dr.
Weiss, who served at Juniper Pharmaceuticals Inc., which was
previously listed on Nasdaq and was subsequently acquired in 2018
by Catalent Inc (NYSE: CTLT), brings with him significant clinical
development experience which will be critical in driving R&D of
Claves’ microbiome-based drug candidates to the next targeted
development milestones. We are also delighted to have Dr. Majzner,
a world-class hematologist and oncologist, on board in supporting
the development of our SACT-1 and related programs.” said Mr. Ian
Huen, the Chief Executive Officer and Executive Director of Aptorum
Group.
Dr. Weiss has over 20 years of experience in the medical field.
He is currently a Physician at Maccabi and Meuchedet Kuppot Health
System and Chairman of the Board of Directors of Todos Medical in
Israel. Dr. Weiss previously held senior roles at both Juniper
Pharmaceuticals, as Head of Clinical Development and Medical
Affairs, and at Teva Pharmaceuticals, as Global Medical Director.
He has also consulted for various medical device and biotech
companies. He owns multiple patents and is the author of numerous
publications in the area of women’s health/gynecology. Dr. Weiss
received his MBA from the George Washington University, his M.D.
from the Ohio State University College of Medicine and his B.A.
from Ramapo College of New Jersey.
Dr. Majzner is an Assistant Professor of Pediatrics in the
Division of Hematology and Oncology at the Stanford University
Medical Center. Prior to joining Stanford, he worked in the
laboratory of Dr. Crystal Mackall at the National Cancer Institute.
His research interests lie in the optimization of chimeric antigen
receptor (CAR) T cell therapies for sarcomas and other solid
tumors. Dr. Majzner received his M.D. from Harvard Medical School,
and completed his pediatric residency at Columbia University and
fellowship in pediatric hematology-oncology at the joint program of
Johns Hopkins University and the National Cancer Institute.
About Aptorum Group
Aptorum Group Limited (Nasdaq: APM) is a pharmaceutical company
dedicated to developing and commercializing novel therapeutics to
tackle current unmet medical needs. Aptorum Group’s current drug
pipeline includes indications in orphan oncology diseases,
infectious diseases, metabolic diseases and woman’s health, a
number of which are targeted to enter clinical trial phases.
Aptorum Group is also launching a women’s health supplement,
dioscorea opposita bioactive nutraceutical tablets marketed under
the brand name NativusWell®.
For more information about Aptorum Group, please visit our
website: www.aptorumgroup.com.
Disclaimer and Forward-Looking
Statements
This press release does not constitute an offer to sell or a
solicitation of offers to buy any securities of Aptorum Group.
This press release includes statements concerning Aptorum Group
Limited and its future expectations, plans and prospects that
constitute “forward-looking statements” within the meaning of the
US Private Securities Litigation Reform Act of 1995. For this
purpose, any statements contained herein that are not statements of
historical fact may be deemed to be forward-looking statements. In
some cases, you can identify forward-looking statements by terms
such as “may," “should," “expects," “plans," “anticipates,"
“could," “intends," “target," “projects," “contemplates,"
“believes," “estimates," “predicts," “potential,” or “continue,” or
the negative of these terms or other similar expressions. Aptorum
Group has based these forward-looking statements, which include
statements regarding projected timelines for application
submissions and trials, largely on its current expectations and
projections about future events and trends that it believes may
affect its business, financial condition and results of operations.
These forward-looking statements speak only as of the date of this
press release and are subject to a number of risks, uncertainties
and assumptions including, without limitation, risks related to its
announced management and organizational changes, the continued
service and availability of key personnel, its ability to expand
its product assortments by offering additional products for
additional consumer segments, development results, the Company’s
anticipated growth strategies, anticipated trends and challenges in
its business, and its expectations regarding, and the stability of,
its supply chain, and the risks more fully described in Aptorum
Group’s Form 20-F and other filings that Aptorum Group may make
with the SEC in the future and the prospectus that received the
French Autorité des Marchés Financiers visa n°20-352 on 16 July
2020. As a result, the projections included in such forward-looking
statements are subject to change and could be materially different
from those described herein.
Aptorum Group assumes no obligation to update any
forward-looking statements contained in this press release as a
result of new information, future events or otherwise.
This announcement is not a prospectus within the meaning of the
Regulation (EU) n°2017/1129 of 14 June 2017 as amended by
Regulations Delegated (EU) n°2019/980 of 14 March 2019 and
n°2019/979 of 14 March 2019.
This press release is provided "as is" without any
representation or warranty of any kind.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200819005586/en/
Investor relations Aptorum
Group limited Investor Relations Department: Tel: +44 020 80929299
Email: investor.relations@aptorumgroup.com Redchip – Financial
Communications United States Investor relations RedChip Companies,
Inc. dave@redchip.com +1 407 491 4498 Actifin – Financial
Communications Europe Investor relations Ghislaine Gasparetto
ggasparetto@actifin.fr +33 1 56 88 11 22
Aptorum (NASDAQ:APM)
Historical Stock Chart
From Aug 2024 to Sep 2024
Aptorum (NASDAQ:APM)
Historical Stock Chart
From Sep 2023 to Sep 2024